tetano
Editor, Senior Moderator
Sci Rep
. 2025 Oct 14;15(1):35800.
doi: 10.1038/s41598-025-19236-8. Clinical features and outcomes of viral respiratory infections in adults during the 2023-2024 winter season
Eleni Rousogianni[SUP] 1 2 [/SUP], Garyfallia Perlepe[SUP] 3 [/SUP], Stylianos Boutlas[SUP] 4 [/SUP], Georgia Rapti[SUP] 3 [/SUP], Evdoxia Gouta[SUP] 3 [/SUP], Eleni Mpaltopoulou[SUP] 3 [/SUP], Giorgos Mpaltopoulos[SUP] 3 [/SUP], Dimitrios Papagiannis[SUP] 5 [/SUP], Aristomenis Exadaktylos[SUP] 6 [/SUP], Konstantinos I Gourgoulianis[SUP] 3 [/SUP], Erasmia Rouka[SUP] 7 [/SUP]
Affiliations
The role and impact of viral infections remain a subject of interest, yet comparative data on influenza A/B, RSV, and SARS-CoV-2 in both hospitalized and non-hospitalized patients are limited. In this observational study, we analyzed data from adult patients with respiratory infections who underwent rapid testing for Influenza A/B, RSV, SARS-CoV-2, and Adenovirus between October 2023 and March 2024. Symptoms at emergency department presentation, laboratory results, risk factors, clinical course, and outcomes were assessed. Among 1,402 patients with respiratory infections, Influenza A was the most prevalent virus and the leading cause of hospitalizations, with the longest stay (mean: 9.86 days). SARS-CoV-2 was the second most common, primarily affecting older patients (mean age: 79 years), associated with the highest in-hospital mortality. RSV ranked third in prevalence, had the highest hospitalization rate among those infected, and was characterized by bronchospasm, with 25% of hospitalized patients requiring high-flow nasal cannula (HFNC). Influenza B primarily affected younger individuals and had a negligible hospitalization rate. SARS-CoV-2 patients sought care the fastest, while RSV patients had the most prolonged symptom duration before seeking medical attention. Despite differences in care-seeking timing, most Flu-A, Flu-B, and SARS-CoV-2 patients recovered within 2-5 days, with no significant difference observed. Vaccine effectiveness against Influenza A was 49.5%. This estimate should be interpreted with caution due to potential confounding by age and comorbidities. These findings offer comparative insights into the clinical burden of respiratory viruses during the 2023-2024 season, reflecting patterns in the post-pandemic era.
Keywords: Adenovirus; Hospitalization; Influenza A/B; RSV; Respiratory infections; SARS-CoV-2; Vaccine effectiveness.
. 2025 Oct 14;15(1):35800.
doi: 10.1038/s41598-025-19236-8. Clinical features and outcomes of viral respiratory infections in adults during the 2023-2024 winter season
Eleni Rousogianni[SUP] 1 2 [/SUP], Garyfallia Perlepe[SUP] 3 [/SUP], Stylianos Boutlas[SUP] 4 [/SUP], Georgia Rapti[SUP] 3 [/SUP], Evdoxia Gouta[SUP] 3 [/SUP], Eleni Mpaltopoulou[SUP] 3 [/SUP], Giorgos Mpaltopoulos[SUP] 3 [/SUP], Dimitrios Papagiannis[SUP] 5 [/SUP], Aristomenis Exadaktylos[SUP] 6 [/SUP], Konstantinos I Gourgoulianis[SUP] 3 [/SUP], Erasmia Rouka[SUP] 7 [/SUP]
Affiliations
- PMID: 41087438
- DOI: 10.1038/s41598-025-19236-8
The role and impact of viral infections remain a subject of interest, yet comparative data on influenza A/B, RSV, and SARS-CoV-2 in both hospitalized and non-hospitalized patients are limited. In this observational study, we analyzed data from adult patients with respiratory infections who underwent rapid testing for Influenza A/B, RSV, SARS-CoV-2, and Adenovirus between October 2023 and March 2024. Symptoms at emergency department presentation, laboratory results, risk factors, clinical course, and outcomes were assessed. Among 1,402 patients with respiratory infections, Influenza A was the most prevalent virus and the leading cause of hospitalizations, with the longest stay (mean: 9.86 days). SARS-CoV-2 was the second most common, primarily affecting older patients (mean age: 79 years), associated with the highest in-hospital mortality. RSV ranked third in prevalence, had the highest hospitalization rate among those infected, and was characterized by bronchospasm, with 25% of hospitalized patients requiring high-flow nasal cannula (HFNC). Influenza B primarily affected younger individuals and had a negligible hospitalization rate. SARS-CoV-2 patients sought care the fastest, while RSV patients had the most prolonged symptom duration before seeking medical attention. Despite differences in care-seeking timing, most Flu-A, Flu-B, and SARS-CoV-2 patients recovered within 2-5 days, with no significant difference observed. Vaccine effectiveness against Influenza A was 49.5%. This estimate should be interpreted with caution due to potential confounding by age and comorbidities. These findings offer comparative insights into the clinical burden of respiratory viruses during the 2023-2024 season, reflecting patterns in the post-pandemic era.
Keywords: Adenovirus; Hospitalization; Influenza A/B; RSV; Respiratory infections; SARS-CoV-2; Vaccine effectiveness.